UC Davis
UC Davis Previously Published Works

Title
Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients

Permalink
https://escholarship.org/uc/item/8hs632xh

Journal
World Journal of Gastroenterology, 22(11)

ISSN
1007-9327

Authors
Li, Yu-Yuan
Ge, Quan-Xing
Cao, Jie
et al.

Publication Date
2016

DOI
10.3748/wjg.v22.i11.3227

Peer reviewed

eScholarship.org Powered by the California Digital Library
University of California

World Journal of Gastroenterology

Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v22.i11.3227

World J Gastroenterol 2016 March 21; 22(11): 3227-3233
ISSN 1007-9327 (print) ISSN 2219-2840 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.

ORIGINAL ARTICLE

Retrospective Study

Association of *Fusobacterium nucleatum* infection with colorectal cancer in Chinese patients

Yu-Yuan Li, Quan-Xing Ge, Jie Cao, Yong-Jian Zhou, Yan-Lei Du, Bo Shen, Yu-Jui Yvonne Wan, Yu-Qiang Nie

Yu-Yuan Li, Quan-Xing Ge, Jie Cao, Yong-Jian Zhou, Yan-Lei Du, Bo Shen, Yu-Qiang Nie, Department of Gastroenterology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, Guangdong Province, China

Yu-Jui Yvonne Wan, Department of Medical Pathology and Laboratory Medicine, University of California, Davis Health Systems, Sacramento, CA 95817, United States

Author contributions: Li YY, Cao J and Zhou YJ designed the research; Ge QX and Shen B performed the experiments; Wan YJY wrote the paper, and Du YL analyzed the data; Nie YQ supervised all the experimental work and revised the manuscript; all authors read and approved the manuscript.

Supported by The National Clinical Key Institute Foundation of Chinese Health and Family Planning Ministry, No. 2013-544.

Institutional review board statement: The study was reviewed and approved by the Guangzhou First People's Hospital Institutional Review Board.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Yu-Qiang Nie, MD, PhD, Professor, Chief, Department of Gastroenterology, Guangzhou First People's Hospital, Guangzhou Medical University, 1 Panfu Road, Guangzhou 510180, Guangdong Province, China. nieyq@medmail.com.cn
Telephone: +86-20-81048720
Fax: +86-20-81048720

Received: September 14, 2015
Peer-review started: September 16, 2015
First decision: October 14, 2015
Revised: October 28, 2015
Accepted: December 8, 2015
Article in press: December 8, 2015
Published online: March 21, 2016

Abstract

AIM: To investigate *Fusobacterium nucleatum* (*F. nucleatum*) abundance in colorectal cancer (CRC) tissues and its association with CRC invasiveness in Chinese patients.

METHODS: The resected cancer and adjacent normal tissues (10 cm beyond cancer margins) from 101 consecutive patients with CRC were collected. Fluorescent quantitative polymerase chain reaction (FQ-PCR) was applied to detect *F. nucleatum* in CRC and normal tissues. The difference of *F. nucleatum* abundance between cancer and normal tissues and the relationship of *F. nucleatum* abundance with clinical variables were evaluated. Fluorescence *in situ* hybridization (FISH) analysis was performed on 22 CRC tissues with the highest *F. nucleatum* abundance by FQ-PCR testing to confirm FQ-PCR results.

RESULTS: The median abundance of *F. nucleatum* in CRC tissues [0.242 (0.178-0.276)] was significantly higher than that in normal controls [0.050 (0.023-0.067)] (P < 0.001). *F. nucleatum* was over-represented in 88/101 (87.1%) CRC samples. The abundance of *F. nucleatum* determined by $2^{-\Delta CT}$ was significantly greater in tumor samples [0.242 (0.178, 0.276)] than in normal

controls [0.050 (0.023, 0.067)] (P < 0.001). The frequency of patients with lymph node metastases was higher in the over-abundance group [52/88 (59.1%)] than in the under-abundance group [0/13 (0%)] (P < 0.005). No significant association of *F. nucleatum* with other clinico-pathological variables was observed (P > 0.05). FISH analysis also found more *F. nucleatum* in CRC than in normal tissues (median number 6, 25th 3, 75th 10 *vs* 2, 25th 1, 75th 5) (P < 0.01).

CONCLUSION: *F. nucleatum* was enriched in CRC tissues and associated with CRC development and metastasis.

Key words: Colorectal cancer; *Fusobacterium nucleatum*; Metastases; Fluorescent quantitative polymerase chain reaction; Fluorescence *in situ* hybridization

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In this study, we demonstrated that *Fusobacterium nucleatum* (*F. nucleatum*) was significantly enriched in resected colorectal cancer (CRC) compared with adjacent normal tissues. *F. nucleatum* infection was associated with CRC development and metastasis. Our results were consistent with two previous reports. To our knowledge, this is the first report on the relationship between *F. nucleatum* and CRC in Chinese patients.

Li YY, Ge QX, Cao J, Zhou YJ, Du YL, Shen B, Wan YJY, Nie YQ. Association of *Fusobacterium nucleatum* infection with colorectal cancer in Chinese patients. *World J Gastroenterol* 2016; 22(11): 3227-3233 Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i11/3227.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i11.3227

INTRODUCTION

Colorectal cancer (CRC) ranks as the third most common cancer and the second most common cause of cancer-related mortality worldwide[1]. The etiology of CRC is still not fully understood. As a huge number of microbial communities are continuously colonized in the gut, some harmful microbiota may play roles in the development of CRC[2,3]. Likewise, the link of some pathogens to cancers, *e.g.*, *Helicobacter pylori* to gastric cancer, human papilloma virus to cervical cancer, and hepatitis B and C virus to hepatocellular carcinoma, has been completely established. These infections are in charge of 18% of cancers[4]. Although the precise mechanisms of the carcinogenesis remain unclear, it is rational to reduce the risk of these cancers by targeting the pathogens. Efforts have been made to explore the possible pathogens involved in CRC development. Once they are identified, it would lead to a breakthrough in the prevention and treatment of CRC.

Fusobacterium nucleatum (*F. nucleatum*) is an anaerobic oral commensal. Besides periodontal disease, it has been documented to be involved in a wide spectrum of disorders, including gastrointestinal diseases, respiratory tract infections, cardiovascular diseases, rheumatoid arthritis, Lemierre's syndrome, and Alzheimer's disease[5]. Currently, accumulating evidence has indicated that a larger number of Fusobacterium spp., especially *F. nucleatum*, is present in tumor tissues and stool samples of CRC patients versus normal controls. A limited number of studies have suggested a positive association of *F. nucleatum* with CRC invasiveness, *e.g.*, lymph node metastasis, but the finding has not been confirmed[6,7]. In the present study, we applied fluorescent quantitative polymerase chain reaction (FQ-PCR) and fluorescence *in situ* hybridization (FISH) to observe the presence of *F. nucleatum* in CRC tissues and to explore the clinical correlation of *F. nucleatum* to CRC invasiveness in Chinese patients.

MATERIALS AND METHODS

Patients

In total, 101 consecutive patients with histologically confirmed colorectal adenocarcinoma (males 55 and females 46, age range 36-82 years) undergoing surgical resections at the Department of General Surgery of Guangzhou First People's Hospital between November 2012 and November 2013 were recruited. The patients who had colorectal tumors other than adenocarcinoma, who received chemotherapy or radiotherapy before operation, and who had comorbid malignancies from other organs were excluded. Fresh CRC and adjacent non-tumor tissues (10 cm beyond cancer margins) from each subject were collected. Samples were snap frozen in liquid nitrogen and then stored at -80 ℃ until use. Samples for histological and FISH examination were fixed in 10% formalin and embedded in paraffin. The stages of CRC were assigned according to TNM and Dukes grades[8]. All 101 patients were enrolled into the FQ-PCR study, among which 22 patients with the highest *F. nucleatum* abundance by FQ-PCR testing were included in microbial FISH examination.

The study protocols complied with the Declaration of Helsinki and were approved by the ethics committee of Guangzhou First People's Hospital affiliated to Guangzhou Medical University. Written consent was obtained from each participant.

Taqman probe-based qPCR assay

Taqman probe-based qPCR was performed on Stepone Plus Real-Time PCR System (Applied Biosystems, Carlsbad, CA, United States) to determine *F. nucleatum* levels in both cancer and matched normal tissues. Levels of 18s rRNA gene in *F. nucleatum* and internal control were measured

simultaneously from the same DNA preparation. DNA was isolated with QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). The primer and probe sequences for *F. nucleatum* were as follows[9-11]: Forward primer, 5′-CAACCATTACTTTAACTCTACCATGTTCA-3′; Reverse primer, 5′-GTTGACTTTACAGAAGGAGATTATGTAAAAATC-3′, Probe, 5′FAM-GTTGACTTTACAGAAGGAGATTATGTAAAAATC-TAMRA3′. *F. nucleatum* probes and primers were synthesized by Life Technologies Company (Carlsbad, CA, United States). Ten microliters of reaction mixture for detection of *F. nucleatum* consisted of 20 ng template DNA, 400 nmol/L of primer set, 400 nmol/L of probe, and 5 μL TaqMan® Universal PCR Master Mix II (Applied Biosystems). The reaction conditions were 10 min at 95 ℃, 40 cycles of 15 s at 95 ℃, and 1 min at 60 ℃. Standard strain of *F. nucleatum* (ATCC10953) and of Escherichia coli (ATCC8739) provided by Microbial Culture Collection Center of Guangdong Institute of Microbiology, China was used as positive and negative controls, respectively. Taqman Ribosomal RNA Control Reagents, including primers and probes (Applied Biosystems) were used to quantify the human endogenous 18s rRNA gene according to the manufacturer's instructions. Amplicons of *F. nucleatum* and 18 s rRNA gene were cloned into pMD 18-T Vector (Takara Biotechnology Co. Ltd, Dalian, China) according to the kit protocol and then over-expressed in *Escherichia coli*-Trans5α (Dongsheng Biotech Co. Ltd, China). Standard curves were constructed with serial 10-fold dilutions of recombinant plasmids. In order to effectively normalize the qPCR data to tissue size, *F. nucleatum* levels were given as $2^{-\Delta CT}$, and the fold changes of *F. nucleatum* abundance in cancer tissue over matched normal colorectal tissue were calculated as $2^{-\Delta\Delta CT}$[6,7]. The relation of *F. nucleatum* infection to the clinical variables (gender, age, histological type, Dukes stage, location, and lymph node metastasis) was evaluated.

FISH analysis

FISH was performed with FISH pharmDx kit (Abbott Vysis Laboratories, Abbott Park, IL, United States) on 22 pair sections of CRC and matched non-cancerous tissues, which were formalin-fixed and paraffin-embedded. Cell nuclei were stained with DAPI. An Oregon-Green 488-conjugated "universal bacterial" probe (EUB338, pB-00159, green) binding 16s rRNA gene at bacterial conserved regions and a Cy3-conjugated Fusobacterium probe (FUSO, pB-0078, red) binding 16s rRNA gene at Fusobacterium specific regions were applied. The sequences of the probes were referred to probeBase (http://www.microbial-ecology.net/probebase/)[12,13]. Probe hybridization was performed at the following conditions: probe concentration 10 μL (5 ng/μL), denaturation at 75 ℃ for 5 min and hybridization at 37 ℃ for 18 h. Slides were imaged on a microscope (Carl Zeiss, Oberkochen, Germany), and the number of *F. nucleatum* was counted. Five random × 40 fields were chosen for evaluation by two pathologists blind to tumor/normal status. The selection criteria of mucosal tissue depth were used, and a minimum of five bacteria visualized by the EUB338 probe per field was required.

Statistical analysis

All statistical analyses were performed using the SPSS 17.0 software package for Windows (SPSS Inc. Chicago, IL, United States). Continuous data were expressed as median (25th percentile, 75th percentile) and examined by the Wilcoxon rank sum test of independent or paired samples. Categorical variables were analyzed with χ^2 test or McNemar test. Bonferroni corrections were applied for multiple comparisons. A *P* value < 0.05 (two tails) was considered statistically significant.

RESULTS

FQ-PCR assay

According to the standard curves, the amplification efficacy of *F. nucleatum* and 18 s rRNA gene was 99.05% and 94.56%, respectively. Compared with the matched normal tissues, *F. nucleatum* load was significantly over-represented in 88 out of 101 (87.13%) CRC samples (Figure 1). The median abundance of *F. nucleatum* determined by $2^{-\Delta\Delta CT}$ was significantly greater in the tumor samples [0.242 (0.178, 0.276)] than that in the matched normal controls [0.050 (0.023, 0.067)] ($P < 0.001$).

Association of F. nucleatum infection with clinicopathologic features of CRC patients

The association of between the clinicopathologic variables of patients and *F. nucleatum* infection is summarized in Table 1. In total, 52 out of 101 (51.5%) CRC patients had regional lymph node metastases. *F. nucleatum* level, expressed as fold changes ($2^{-\Delta\Delta CT}$, cancer versus normal, in the lymph node metastases group [1538.05 (479.21, 2643.12)] was significantly higher than that [212.87 (37.25, 257.37)] in the non-metastases group ($P < 0.005$). Lymph node metastases were present in 52 out of 88 (59.1%) patients with *F. nucleatum* over-abundance (fold changes > 1), and in 0 out of 13 (0%) patients with *F. nucleatum* under-abundance (fold change < 1) ($P < 0.005$). No significant association of *F. nucleatum* infection with other clinicopathological variables, *e.g.*, patient's gender, age, cancer stages, location, infiltration depth, and pathological differentiation, was observed ($P > 0.05$) (Table 1).

FISH detection

F. nucleatum was determined in 22 paired specimens of CRC and matched non-cancerous controls by FISH. *F. nucleatum* stained with FUSO probe (in red) was



Figure 1 Fold change of *Fusobacterium nucleatum* abundance in colorectal cancer *vs* matched normal tissues (n = 101). $2^{-\Delta\Delta CT}$ represented the fold change of *Fusobacterium nucleatum* load in cancer tissue over matched normal tissues. The numbers in Y-axis indicated the $2^{-\Delta\Delta CT}$ value of each patient.

Table 1 Association of *Fusobacterium nucleatum* infection with clinicopathologic variables (n = 101)

	n	Cancer/normal tissue fold changes [$2^{-\Delta\Delta CT}$(Median)]	P value
Gender			
Male	55	1029.19 (418.27, 6517.82)	
Female	46	7348.74 (529.05, 8827.37)	0.539
Age (yr)			
< 65	52	1100.68 (671.32, 5624.36)	
≥ 65	49	677.03 (502.86, 4946.93)	0.375
Location of CRC			
Rectum	59	1045.11 (824.66, 7567.37)	
Colon	42	6844.72 (1735.91, 8141.03)	0.456
Differentiation			
Moderately and high	59	524.95 (345.19, 2341.54)	
Low	42	1158.67 (432.61, 1988.30)	0.412
Tissue infiltration			
T1 + T2	25	1029.20 (213.76, 1365.41)	
T3 + T4	76	837.89 (196,36, 2679.33)	0.676
Lymph node metastasis			
N0	49	212.87 (37.25, 257.37)	
N1 + N2	52	1538.05 (479.21, 2643.12)	0.005
Duke stages			
A	12	739.50 (132.24, 1615.65)	
B	36	837.46 (264.33, 1489.65)	0.368
C	46	1132.31 (289.73, 1688.72)	
D	7	1356.05 (311.03, 2321.73)	

found to be enriched within the colonic mucosa of CRC (median number 6, 25th 3, 75th 10) compared to the normal control tissues (median number 2, 25th 1, 75th 5) (Figure 2) (P < 0.01).

DISCUSSION

The human gastrointestinal lumen is harbored by more than 1000 species of microorganisms, which bring about beneficial and deleterious effects on the host. High abundance of Enterococcus, Escherichia/Shigella, Klebsiella, Streptococcus, Peptostreptococcus, Bacteroides-Prevotella, and low abundance of Lachnospiraceae/Roseburia, clostridia have been found in the gut compartment of CRC patients compared with normal controls[14-17]. For a long time, it has been believed that the dysbiosis in the gut results in a variety of colorectal diseases, including CRC, but no specific bacterium has been confirmed[14-17]. Recently, sequence-based investigations have provided us much valuable information in this field. In 2012, two North American studies published in *Genome Research* declared that a periodontal pathogen, *i.e.*, *F. nucleatum,* was overabundant in CRC tissues. Using a whole-genome sequencing technique, Kostic *et al*[18] identified the enrichment of DNA sequences of Fusobacterium spp. in CRC compared with control samples. Among them, *F. nucleatum* was the most dominant phylotype. Using RNA-sequencing approaches, Castellarin *et al*[7] also observed a large amount of Fusobacterium spp. in CRC versus normal tissues. In addition, they found a positive association of *F. nucleatum* over-abundance with lymph node metastasis. Afterwards, several studies confirmed overload of *F. nucleatum* in CRC tissues[3,6,19,20]. Currently, two studies revealed *F. nucleatum* to be a poor prognostic factor of CRC patients. Using molecular pathological epidemiology database of 1069 CRC patients, Mima *et al*[21] revealed a link between high *F. nucleatum* DNA load in CRC tissue and shorter survival of patients. Flanagan *et al*[6] found a significantly longer survival time in CRC patients with low *F. nucleatum* levels than those with moderate and high levels.

A persuasive interpretation of the above data is an important issue. Firstly, is *F. nucleatum* a cause or a consequence of CRC? So far, increasing evidence is in favor of the "cause" hypothesis, as emerging data have demonstrated that *F. nucleatum* at first induced precancerous lesions (*e.g.*, hyperplastic polyps and adenomas), which eventually progressed to CRC[6,10,22,23]. In addition, a number of pathogenetic studies supported the carcinogenic roles of *F. nucleatum*. As the mucosa adherent bacteria, *F. nucleatum* had ability to adhere to and invade epithelial cell[7,23-26]. *F. nucleatum* shuttled non-invasive bacteria, in particular Campylobacter spp. and Streptococcus into the host cell as mixed



Figure 2 Enrichment of *Fusobacterium nucleatum* in colorectal cancer detected by FISH. Graph A: Colorectal cancer (CRC) specimen stained with DAPI. Cell nuclei were stained in blue; B: CRC specimen stained with both DAPI and universal bacterial probe (EUB338). Bacterial conserved regions were stained in green; C: CRC specimen stained with both DAPI and Fusobacterium specific probe (FUSO). The *Fusobacterium nucleatum* (*F. nucleatum*) specific regions were stained in red; D: CRC specimen triply stained with DAPI, EUSO and EUB338. Cell nuclei (in blue), bacterial conserved regions (in green) and *F. nucleatum* specific regions (in red) were clearly visible (all × 400).

species synergism[27]. By binding to E-cadherin on the epithelial cell, *F. nucleatum* stimulated FadA, which activated β-catenin signaling pathways and up-regulated oncogene expression[17]. *F. nucleatum* induced inflammation by releasing RNA into the host cell and activating nuclear factor kappa B[17]. *F. nucleatum* increases cytokines, in particular tumor necrosis factor-α and interleukin (IL)-10[20]. *F. nucleatum* induced a number of pathogenesis-related events, including CpG island methylator phenotype (CIMP), microsatellite instability (MSI), and genetic mutations in *BRAF*, *KRAS*, *TP53*, *CHD7*, and *CHD8*[28]. *F. nucleatum* reduced CD3+ T cell density in CRC tissues[29]. *F. nucleatum* regulated the tumor immune microenvironment through E-cadherin/β-catenin signaling[30]. Secondly, are gut microbiota other than *F. nucleatum* also enriched in CRC tissues and do they enhance CRC invasiveness? In our ongoing study, the five most suspected bacteria related to CRC in literature[14-17,31] were quantified in the same CRC population. *F. nucleatum*, Enterotoxigenic Bacteroides fragilis (ETBF), and *Enterococcus faecalis* (*E. faecalis*) were significantly enriched in CRC compared to the matched non-cancerous tissues, while no difference were found in enteropathogenic *Escherichia coli* and *Streptococcus gallolyticus* (*S. gallolyticus*). The positive rate of *F. nucleatum* overload (87.13%) was much higher than those of ETBF (61.67%) and *E. faecalis* (55.04%) (unpublished data). Our study was consistent with a recent cohort enrolling six bacteria, which demonstrated that *F. nucleatum* was the only bacterium significantly overabundant in CRC compared with normal tissues, and *F. nucleatum* and ETBF were associated with the clinicopathological features of patients[31]. Based on above observations, we infer that *F. nucelatum* is specifically enriched in CRC and enhances CRC invasiveness.

Recently, the emerging science of molecular pathways has shed light on the pathogenesis of CRC. MSI, chromosomal instability, and CIMP are common genetic changes, while microRNAs, DNA methylation, and histone modifications are analyzed in epigenesis. Interactions between genetic and epigenetic factors are involved in the carcinogenesis of *F. nucleatums*[32-34]. Environmental risk factors, *e.g.*, changes in diet and lifestyle, may affect nuclear receptors on the gut microbiota and induce carcinogenesis through molecular pathways[35]. Furthermore, molecular pathological epidemiology (MPE), a multidisciplinary investigation into the relationship among genetic factors, molecular signatures, and disease progression, provides insights into the pathogenetic process as well as therapeutic optimization[35-37]. Using a MPE database of 1069 CRC patients, Mima *et al*[21] successfully uncovered the association of *F. nucleatum* DNA load with the prognosis of patients.

There are a few limitations of this study. Firstly, we have not used the innovative concept of molecular sciences to design the study. Secondly, we have not included more intestinal bacterial species in addition to *F. nucleatum*. On the whole, our results still reflected the main features in Chinese people. Further larger studies are needed to examine these findings.

In conclusion, our results demonstrated that *F. nucleatum* was enriched in CRC tissue, and *F. nucleatum* abundance was positively associated with lymph node metastasis of CRC patients. There were no geographical and ethnic differences in the association. To our knowledge, this is the first report of its kind in Chinese patients.

COMMENTS

Background

Increasing evidence suggests that *Fusobacterium nucleatum* (*F. nucleatum*) infection in the colon plays a role in the pathogenesis of colorectal cancer (CRC). The clinical correlation of *F. nucleatum* load with CRC progression has not been fully established, especially in Chinese patients.

Research frontiers

This study investigated the relationship between *F. nucleatum* infection and the presence of CRC and the association of *F. nucleatum* abundance with CRC invasiveness in Chinese patients.

Innovations and breakthroughs

In this study, the authors demonstrate that *F. nucleatum* is significantly enriched in CRC tissues from surgical resections compared with adjacent normal tissues. *F. nucleatum* abundance is associated with CRC metastasis. These results are consistent with previous reports and confirm that there is no geographical and ethnic difference in the association. This is the first report of this important data in Chinese patients.

Applications

As *F. nucleatum* is identified as a pathogen of CRC, it may be a new drug target for the future prevention and treatment of CRC.

Terminology

CRC is one of most common cancers worldwide. The etiology of CRC is still not fully understood. *F. nucleatum* is an anaerobic oral commensal. Currently, increasing evidence suggests that *F. nucleatum* is involved in a wide spectrum of illness, including CRC. Fluorescent quantitative polymerase chain reaction and fluorescence *in situ* hybridization are laboratory techniques commonly used in practice.

Peer-review

The authors of this study have investigated the relationship between *F. nucleatum* infection with colorectal cancer in Chinese patients.

REFERENCES

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Rowland IR**. The role of the gastrointestinal microbiota in colorectal cancer. *Curr Pharm Des* 2009; **15**: 1524-1527 [PMID: 19442169]

3 **Warren RL**, Freeman DJ, Pleasance S, Watson P, Moore RA, Cochrane K, Allen-Vercoe E, Holt RA. Co-occurrence of anaerobic bacteria in colorectal carcinomas. *Microbiome* 2013; **1**: 16 [PMID: 24450771 DOI: 10.1186/2049-2618-1-16]

4 **Parkin DM**. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006; **118**: 3030-3044 [PMID: 16404738 DOI: 10.1002/ijc.21731]

5 **Han YW**. Fusobacterium nucleatum: a commensal-turned pathogen. *Curr Opin Microbiol* 2015; **23**: 141-147 [PMID: 25576662 DOI: 10.1016/j.mib.2014.11.013]

6 **Flanagan L**, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 1381-1390 [PMID: 24599709 DOI: 10.1007/s10096-014-2081-3]

7 **Castellarin M**, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. *Genome Res* 2012; **22**: 299-306 [PMID: 22009989 DOI: 10.1101/gr.126516.111]

8 **Williams ST**, Beart RW. Staging of colorectal cancer. *Semin Surg Oncol* 1992; **8**: 89-93 [PMID: 1615269]

9 **Gaetti-Jardim E**, Marcelino SL, Feitosa AC, Romito GA, Avila-Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. *J Med Microbiol* 2009; **58**: 1568-1575 [PMID: 19679682 DOI: 10.1099/jmm.0.013383-0]

10 **Kostic AD**, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* 2013; **14**: 207-215 [PMID: 23954159 DOI: 10.1016/j.chom.2013.07.007]

11 **Gentili V**, Gianesini S, Balboni PG, Menegatti E, Rotola A, Zuolo M, Caselli E, Zamboni P, Di Luca D. Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed ™ Sorbact™. *Eur J Clin Microbiol Infect Dis* 2012; **31**: 1523-1529 [PMID: 22113306 DOI: 10.1007/s10096-011-1473-x]

12 **Loy A**, Arnold R, Tischler P, Rattei T, Wagner M, Horn M. probeCheck--a central resource for evaluating oligonucleotide probe coverage and specificity. *Environ Microbiol* 2008; **10**: 2894-2898 [PMID: 18647333 DOI: 10.1111/j.1462-2920.2008.01706.x]

13 **Swidsinski A**, Dörffel Y, Loening-Baucke V, Theissig F, Rückert JC, Ismail M, Rau WA, Gaschler D, Weizenegger M, Kühn S, Schilling J, Dörffel WV. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. *Gut* 2011; **60**: 34-40 [PMID: 19926616 DOI: 10.1136/gut.2009.191320]

14 **Tremaroli V**, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. *Nature* 2012; **489**: 242-249 [PMID: 22972297 DOI: 10.1038/nature11552]

15 **Sekirov I**, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. *Physiol Rev* 2010; **90**: 859-904 [PMID: 20664075 DOI: 10.1152/physrev.00045.2009]

16 **Bustos Fernandez LM**, Lasa JS, Man F. Intestinal microbiota: its role in digestive diseases. *J Clin Gastroenterol* 2014; **48**: 657-666 [PMID: 24921207 DOI: 10.1097/MCG.0000000000000153]

17 **Allen-Vercoe E**, Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC? *Immunol Lett* 2014; **162**: 54-61 [PMID: 24972311 DOI: 10.1016/j.imlet.2014.05.014]

18 **Kostic AD**, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. *Genome Res* 2012; **22**: 292-298 [PMID: 22009990 DOI: 10.1101/gr.126573.111]

19 **Shen XJ**, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, Jovov B, Abdo Z, Sandler RS, Keku TO. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. *Gut Microbes* 2010; **1**: 138-147 [PMID: 20740058 DOI: 10.4161/gmic.1.3.12360]

20 **McCoy AN**, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. *PLoS One* 2013; **8**: e53653 [PMID: 23335968 DOI: 10.1371/

journal.pone.0053653]
21 **Mima K**, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. *Gut* 2015; Epub ahead of print [PMID: 26311717 DOI: 10.1136/gutjnl-2015-310101]
22 **Ito M**, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M, Takahashi H, Yoshii S, Takenouchi T, Hasegawa T, Okita K, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. *Int J Cancer* 2015; **137**: 1258-1268 [PMID: 25703934 DOI: 10.1002/ijc.29488]
23 **Chen W**, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. *PLoS One* 2012; **7**: e39743 [PMID: 22761885 DOI: 10.1371/journal.pone.0039743]
24 **Sonnenburg JL**, Angenent LT, Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? *Nat Immunol* 2004; **5**: 569-573 [PMID: 15164016 DOI: 10.1038/ni1079]
25 **Oswald IP**. Role of intestinal epithelial cells in the innate immune defence of the pig intestine. *Vet Res* 2006; **37**: 359-368 [PMID: 16611553]
26 **Strauss J**, White A, Ambrose C, McDonald J, Allen-Vercoe E. Phenotypic and genotypic analyses of clinical Fusobacterium nucleatum and Fusobacterium periodonticum isolates from the human gut. *Anaerobe* 2008; **14**: 301-309 [PMID: 19114111 DOI: 10.1016/j.anaerobe.2008.12.003]
27 **Rubinstein MR**, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. *Cell Host Microbe* 2013; **14**: 195-206 [PMID: 23954158 DOI: 10.1016/j.chom.2013.07.012]
28 **Tahara T**, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. *Cancer Res* 2014; **74**: 1311-1318 [PMID: 24385213 DOI: 10.1158/0008-5472.CAN-13-1865]
29 **Mima K**, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. *JAMA Oncol* 2015; **1**: 653-661 [PMID: 26181352 DOI: 10.1001/jamaoncol.2015.1377]
30 **Bashir A**, Miskeen AY, Bhat A, Fazili KM, Ganai BA. Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. *Eur J Cancer Prev* 2015; **24**: 373-385 [PMID: 25569450 DOI: 10.1097/CEJ.0000000000000116]
31 **Viljoen KS**, Dakshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. *PLoS One* 2015; **10**: e0119462 [PMID: 25751261 DOI: 10.1371/journal.pone.0119462]
32 **Colussi D**, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. *Int J Mol Sci* 2013; **14**: 16365-16385 [PMID: 23965959 DOI: 10.3390/ijms140816365]
33 **Bardhan K**, Liu K. Epigenetics and colorectal cancer pathogenesis. *Cancers* (Basel) 2013; **5**: 676-713 [PMID: 24216997 DOI: 10.3390/cancers5020676]
34 **Zoratto F**, Rossi L, Verrico M, Papa A, Basso E, Zullo A, Tomao L, Romiti A, Lo Russo G, Tomao S. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. *Tumour Biol* 2014; **35**: 6195-6206 [PMID: 25051912 DOI: 10.1007/s13277-014-1845-9]
35 **Bishehsari F**, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. *World J Gastroenterol* 2014; **20**: 6055-6072 [PMID: 24876728 DOI: 10.3748/wjg.v20.i20.6055]
36 **Ogino S**, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011; **60**: 397-411 [PMID: 21036793 DOI: 10.1136/gut.2010.217182]
37 **Ogino S**, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. *Mod Pathol* 2013; **26**: 465-484 [PMID: 23307060 DOI: 10.1038/modpathol.2012.214]

P- Reviewer: Marin JJG, Ogino S **S- Editor**: Qi Y
L- Editor: Filipodia **E- Editor**: Zhang DN

Published by **Baishideng Publishing Group Inc**
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

ISSN 1007-9327

© 2016 Baishideng Publishing Group Inc. All rights reserved.